Arrowstreet Capital, Limited Partnership Allogene Therapeutics, Inc. Transaction History

Arrowstreet Capital, Limited Partnership

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 12, 2020	SELL	$32.38 - $44.96 $4.39 Million - $6.1 Million	-135,700 Closed	0 $0
Q2 2020 Aug 12, 2020	BUY	$18.39 - $54.04 $2.5 Million - $7.33 Million	135,700 New	135,700 $5.81 Million
Q2 2019 Aug 14, 2019	SELL	$25.56 - $31.09 $728,460 - $886,065	-28,500 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$24.82 - $32.54 $707,370 - $927,390	28,500 New	28,500 $824,000

177

139M

75.8K

52.8K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $234M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.